biostudies-literatureShoham SNational Center for Advancing Translational SciencesNCATS NIH HHSNIAID NIH HHSMoriah FundNIHMental Wellness FoundationNational Institute of Allergy and Infectious DiseasesDivision of Intramural Research NIAID NIHHealthNetwork FoundationOctapharmaJPEO-CBRNDShear Family FoundationDHAe477-e486https://www.ebi.ac.uk/biostudies/studies/S-EPMC9129191biostudies-literatureUnknown76(3)<h4>Background</h4>The efficacy of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) convalescent plasma (CCP) for preventing infection in exposed, uninfected individuals is unknown. CCP might prevent infection when administered before symptoms or laboratory evidence of infection.<h4>Methods</h4>This double-blinded, phase 2 randomized, controlled trial (RCT) compared the efficacy and safety of prophylactic high titer (≥1:320 by Euroimmun ELISA) CCP with standard plasma. Asymptomatic participants aged ≥18 years with close contact exposure to a person with confirmed coronavirus disease 2019 (COVID-19) in the previous 120 hours and negative SARS-CoV-2 test within 24 hours before transfusion were eligible. The primary outcome was new SARS-CoV-2 infection.<h4>Results</h4>In total, 18Clinical infectious diseases : an official publication of the Infectious Diseases Society of AmericaTransfusing Convalescent Plasma as Post-Exposure Prophylaxis Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: A Double-Blinded, Phase 2 Randomized, Controlled Trial.PMC9129191U24 TR001609R01 AI152078UL1 TR001409UL1TR003098UL1 TR0014143R01AI152078-01S1U24TR001609-S3Huaman MAPatel BHanley DLane KCluzet VEhrhardt SRausch WSingleton JRPark HSPaxton JHPetrini JCordisco MEJabs DAKarlen NCasadevall AMcBee NPekosz AKassaye SGGerber JBloch EMLevine ACBroderick PCaputo CAMerlo CZand MBowen ACurrier JShoham SBlair PWCachay EShade DMHammel JThomas DLBaksh SMosnaim GGebo KForthal DJedlicka ANaeim ACruser DGniadek TZenilman JMKlein SShapiro JRTobian AARLaeyendecker OSullivan DJGawad ALMeisenberg BAnjan SSutcliffe CFukuta YYarava AAppel LLau BAllen ESfalseTransfusing Convalescent Plasma as Post-Exposure Prophylaxis Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: A Double-Blinded, Phase 2 Randomized, Controlled Trial.<h4>Background</h4>The efficacy of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) convalescent plasma (CCP) for preventing infection in exposed, uninfected individuals is unknown. CCP might prevent infection when administered before symptoms or laboratory evidence of infection.<h4>Methods</h4>This double-blinded, phase 2 randomized, controlled trial (RCT) compared the efficacy and safety of prophylactic high titer (≥1:320 by Euroimmun ELISA) CCP with standard plasma. Asymptomatic participants aged ≥18 years with close contact exposure to a person with confirmed coronavirus disease 2019 (COVID-19) in the previous 120 hours and negative SARS-CoV-2 test within 24 hours before transfusion were eligible. The primary outcome was new SARS-CoV-2 infection.<h4>Results</h4>In total, 182023-01-01T00:00:00Z2023 Feb2026-05-09T15:34:46.544Z2025-02-19T03:58:38.877ZS-EPMC91291913557950910.1093/cid/ciac372